Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
about
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersComparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersDeferasirox for managing iron overload in people with myelodysplastic syndromeDeferasirox for managing iron overload in people with myelodysplastic syndromeDeferasirox for managing iron overload in patients with myelodysplastic syndromeClinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsTransfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic SyndromesCancer cells with irons in the fireSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyMesenchymal stem cells in pathogenesis of myelodysplastic syndromesIron chelation therapy in myelodysplastic syndromes: where do we stand?Guidelines on haemovigilance of post-transfusional iron overloadSomatic SF3B1 mutation in myelodysplasia with ring sideroblastsMDS prognostic scoring systems – past, present, and futureDecision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome.Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemRefractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromesIncreased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes.Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.Loss of SIMPL compromises TNF-alpha-dependent survival of hematopoietic progenitors.Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO studyLiver iron content determination by magnetic resonance imaging.Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: Results of a meta-analysis of observational studies.Iron chelation therapy with deferasirox results in improvement of liver enzyme level in patients with iron overload-associated liver dysfunction.Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.Iron chelation therapy in myelodysplastic syndromes.Hepcidin levels and their determinants in different types of myelodysplastic syndromes.Current therapy of myelodysplastic syndromesDeferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavengingThere's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.The search for better prognostic models in myelodysplastic syndromesThe different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes
P2860
Q24186615-4F3A3D96-1485-4AA9-9791-DC37D5C4BC49Q24187692-E1FD9640-1B56-49D2-8E87-EEF1F3AF4B6CQ24193067-18907351-BAA2-4ABD-ABD6-E0B543084F26Q24236532-B9A2A412-CF31-4DA9-8ABA-D815ED60AB13Q24242437-24B76379-88B7-4777-84E4-A2A32340495EQ24629306-5F3CAAC9-0597-4C1E-A7DC-846C61BA4C6CQ26748281-FF7B7333-7940-4A23-B693-E137FFED2C9AQ26851312-C611593F-A095-4503-BA08-806043D65733Q27010653-B41E1692-E73D-4D5B-BD6A-8CC8EA2C2F23Q27011323-D527A14C-D97F-479D-94C6-436E7F6E7828Q27011747-785799F5-B805-47B4-8810-33FD1DEA570EQ27022721-5EBA18CE-14F5-46DB-8F06-780176F2A9DAQ27851675-5E85FC73-C74F-42D6-AA7E-DE55920F3F0CQ28082460-B3D2B8A7-CAE2-421A-AFDE-063671581897Q30240190-11905F77-BE9E-4659-8B1D-0D3F6037BB0BQ30249108-5C650E2A-B3BA-4CFE-85BC-8B77DB79AA7EQ30837329-43F7EF9B-6189-415C-A44B-5BCAC94E785BQ33373984-5C2F62BF-046B-48B5-A1F5-6ECBA9806AACQ33380307-75427420-37D2-404D-BF28-19B923C2CAC2Q33388797-D87CAE0D-BFCA-426D-A0EC-C6BCF0493634Q33393647-27A90B26-7AAF-4554-8FEA-93D2A32408E7Q33397165-6EF500D5-BF4E-480E-8922-992D0EC8ED44Q33405829-A386C1F6-31F6-492B-9CB3-5C756508B5DAQ33411923-9BE4AD71-F346-4B96-B224-531E3281F6AAQ33427880-7E75B068-3DA2-41ED-9297-1D0934D00C59Q33595649-158F483D-409C-4A40-8C67-E98487D02F39Q33625589-C0B52015-08B9-4391-A462-8FF6E6D2ADCDQ33707461-0777093A-EB17-4B7E-AFEF-7D88D838C8B9Q33764777-ADE01B13-B197-4D3C-B26F-5C6D41879313Q33806889-79A93DD8-758C-4E0F-9408-164C594E8CCDQ33889442-CF88D4EE-4FC5-4176-8FB6-5A13E1E6F65DQ33903052-16FC61BA-E389-4300-8568-25720E13D8D8Q34002840-33CA46C1-8C57-4556-A012-F5D292C7E2F2Q34008796-3FAA6AAD-A07F-467F-8135-3DECB9971A1FQ34013796-4C790EB3-8C00-4375-BC0E-988491A1C03BQ34032208-E92AA748-2C39-4FD3-B5DE-D52C4509E06AQ34049017-45016443-AFB1-4175-8142-38C698F9FBCFQ34106883-49DCE666-F222-4B47-859C-28CEF51D623EQ34386812-96457DAE-0333-4ABA-A954-FBF24E00A113Q34429788-FE8F7A30-90C4-4908-B5BF-92A9D3CCA692
P2860
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Prognostic factors and life ex ...... for clinical decision making.
@en
Prognostic factors and life ex ...... for clinical decision making.
@nl
type
label
Prognostic factors and life ex ...... for clinical decision making.
@en
Prognostic factors and life ex ...... for clinical decision making.
@nl
prefLabel
Prognostic factors and life ex ...... for clinical decision making.
@en
Prognostic factors and life ex ...... for clinical decision making.
@nl
P2093
P50
P356
P1476
Prognostic factors and life ex ...... s for clinical decision making
@en
P2093
Cristiana Pascutto
Erica Travaglino
Luca Malcovati
Margherita Maffioli
Marina Boni
Mario Cazzola
Mario Lazzarino
Matteo Giovanni Della Porta
Rosangela Invernizzi
P304
P356
10.1200/JCO.2005.01.7038
P407
P577
2005-09-26T00:00:00Z